Purpose: Adjuvant chemotherapy versus observation and chemotherapy at progression was evaluated in 162 patients in a prospective randomized multicenter study. We also evaluated DNA-measurements as an additional prognostic factor.
Introduction
Ovarian cancer is the sixth most common female malignancy worldwide with approximately 141,000 new cases and 106,000 deaths annually. Approximately one third of the cases present with localized (early stage) disease; International Federation of Obstetrics and Gynecology (FIGO) stage I or II [1, 2] . The prognosis for these women is much better than for patients with FIGO stage III or IV. The five-year survival rates reported for patients with early stage disease have varied, in part due to differences in surgical staging: from 50%-90% and 30%-80% for patients with stage I and II disease, respectively [3, 4] . Patients with early ovarian cancer not cured by surgery have subclinical metastases most commonly in the peritoneal cavity, but occasionally also in extra-peritoneal locations. The risk for early peritoneal seeding depends on stage as well as biological factors not included in the current FIGO 1988 staging system [5] .
A major advance in the management of early ovarian cancer has been the identification of prognostic factors predictive of a high risk for micrometastatic disease and progression. FIGO stage I disease should, therefore, based upon the prognostic factors, be divided into subgroups. Early reports identified poor differentiation, histologic type (clear cell carcinoma), dense adhesions, large volume ascites, and older age at diagnosis as independent, negative prognostic factors [6] [7] [8] [9] [10] [11] [12] [13] . Most of the prognostic factors mentioned above have significant shortcomings due to their subjectivity and lack of reproducibility [14] , and low prognostic power. Therefore, the search for additional prognostic factors that can be more objectively measured with better reproducibility has intensified. One of the more promising candidates in this regard is DNA content measurement (ploidy and S-phase fraction) [15] [16] . At the Norwegian Radium Hospital (NRH) we have retrospectively analyzed traditional prognostic factors in conjunction with DNA ploidy measurements in a series of 290 patients with FIGO stage I epithelial invasive ovarian carcinoma [17] . Multivariate analysis confirmed earlier studies [6] [7] [8] [9] [10] [11] [12] [13] , which demonstrated that grade (in non-clear cell carcinomas) was the most powerful predictor of disease free survival (DFS). In addition, DNA ploidy and FIGO 1986 sub-stage was identified as new independent prognostic factors.
Do any of the existing adjuvant therapies benefit high-risk patients?
The universally accepted initial treatment of patients with early resectable ovarian cancer is surgical. Comparisons of survival between non-randomized studies using different types of adjuvant therapy or no adjuvant therapy are not informative. Following the introduction of cisplatin, four prospective randomized studies of adjuvant cisplatin versus 32 P have been performed [18] [19] [20] [21] [22] . Equivalency in efficacy (prevention of recurrence) was observed in each study. Without an untreated control group the advantage of a specific adjuvant therapy is not evident [21] .
In a multicenter trial The Gruppo Italiano Collaborativo Oncologica Gynecologica (GICOG) randomized 83 patients with stage IA and IB, grade 2 and 3 tumors between cisplatin and observation [22] . The median follow-up was 69 months. The five-year disease-free survival (DFS) was 83% for cisplatin and 64% for the control group. However, no difference in overall survival (OS) could be detected (87% vs. 81%).
Only a large prospective trial for early poor prognosis ovarian cancer patients with an untreated control arm will be able to resolve the question of whether any adjuvant therapy confers a survival advantage. In 1992 we initiated a Scandinavian, prospective, randomized trial in high-risk FIGO (1988) stage I ovarian carcinoma comparing adjuvant carboplatin with an observation arm [23] . We had two goals, first to answer the question of the role of adjuvant postoperative therapy, and secondly to test prospectively DNA ploidy as an independent prognostic factor in stage I high-risk ovarian cancer. Carboplatin was used instead of cisplatin because it had been shown that carboplatin was equally effective in generating response in ovarian cancer and possessed lower oto-, neuro-and nephrotoxicity than cisplatin [24, 25] .
nitrogen, serum creatinine, glomerular filtration (GFR) and liver function tests; 6) informed consent.
Protocol exclusion criteria
Exclusion criteria included: 1) previous treatment with chemo-or radiotherapy; 2) previous or concomitant other malignant disease, with the exception of adequately treated basal cell carcinoma of the skin, and carcinoma in situ of the cervix; 3) expected inadequacy of follow-up; 4) ECOG performance status > 3; 5) interval between staging laparotomy and randomization of more than six weeks.
Patients
From May 1992 to September 1997 210 patients were eligible for randomization; 35 patients refused randomization and 175 patients were randomized. Thirteen patients were subsequently found to be ineligible: four had borderline tumors, four were older than seventyone years, four had stage I grade 1 diploid tumors and one had cancer of the fallopian tube.
Staging and surgery before randomization

Non-invasive staging
Staging was performed according to the guidelines in the FIGO 1988 classification. Initial noninvasive staging included chest radiography and intravenous pyelography. When clinically indicated, ultrasonography, barium enema, proctosigmoidoscopy and computerized tomography for determination of paraaortic and pelvic lymph nodes status were performed. In cases of suspected lymph node metastases, cytologic or histologic confirmation of the diagnosis was recommended.
Compulsory surgical procedure
The surgical treatment consisted of total abdominal hysterectomy, bilateral salping-oophorectomy, and infracolic omentectomy. Primary laparotomy was to be performed through a vertical incision of sufficient length to allow the evaluation of the abdominal contents and the sites at high risk for surface metastases. The tumor capsule had to be examined for rupture and excrescences. Dense adhesions were defined as any adherences requiring sharp dissection. Peritoneal washings were performed in all patients, except those with ascites. Biopsies or fine needle aspiration of all suspicious intraperitoneal or retroperitoneal lesions were to be performed.
Optional surgical procedure
The following procedures were optional, but recommended: 1) scraping of the diaphragm for cytologic examination, 2) random biopsies of bladder peritoneum, cul-de-sac, right and left paracolic gutter, of the pelvic sidewall, and at the site of the primary tumor, and 3) para-aortic and pelvic lymph node sampling or lymphadenectomy. The number and location of the biopsies was recorded.
Patients and methods
Protocol entry criteria
Patients fulfilling the following criteria were included: 1) histologically invasive epithelial ovarian carcinoma; 2) FIGO stage I non-clear cell carcinoma aneuploid grade 1, FIGO stage I non-clear cell carcinoma grade 2 and 3, or FIGO stage I clear cell carcinoma; 3) surgical treatment and staging before randomization according to the minimal criteria mentioned under surgical staging procedure below; 4) age younger than 71 years; 5) adequate bone marrow function as evidence by a normal leukocyte and platelet count, as well as normal blood urea Histologic classification and grading All histologic sections were reviewed by reference pathologists from the participating countries without their knowledge of the clinical outcome. Histological classification was performed using the criteria defined by the World Health Organization (WHO). All tumors, except for clear cell carcinomas, were graded according to the WHO histologic grading system as grade 1, 2 or 3 [26] ,
DNA flow cytometry
The methods used for cell extraction from sections cut from paraffin embedded tissue, preparations of nuclei, staining and flow cytometry (16) 68 (84) 29 (36) 6 (7) 46 (57) 19 (24) 14 (17) 20 (25) 21 (26) 2 (3) 5 (6) 20 (25) 15 (19) 25 (31) 21 (26) 64 (79) 17 (21) 50 (62) 31 (38) 42 (52) 39 (48) 53 (65) 28 (35) 1(1) 13 (16) 62 (77) 5 (6) 25 (31) 56 (69) 18 (22) 17 (22) 40 (49) 6 (7) 36 (44) 8 (10) 37 (46) Carboplatin, number Control, number of evaluable patients of evaluable (n = 81) patients (n -81) NS 54(30-71) 15 (19) 66 (81) 37 (45) 3 (4) 41 (51) 13 (16) 14 (17) 21 (22) 24 (30) 6 (7) 3 (4) 23 (28) 21 (26) 13 (17) 24 (30) 70 (86) 11 (14) 48 (59) 33 (41) 41 (51) 40 (49) 57 (70) 24 (30) 3 (4) 16 (20) 53 (65) 9 (11) 28 (35) 53 (65) 19 (23) 13 (16) 42 (50) 7 (9) 42 (52) 5 (6) 34 ( analysis have been described in detail previously [27, 28] . Classification of the histograms was performed according to the recommendation of The Society of Analytical Cytology [29] without knowledge of the final outcome. DNA histograms with a coefficient of variation (CV) > 10% was disregarded. The photo multiplier voltage was adjusted for each sample to place the first peak Gi (i.e., the one having the lowest ploidy) in channel 50. This peak was considered to be DNA diploid. Evidence of an additional G| peak indicated the presence of DNA non-diploid. DNA non-diploid tumors were further divided into aneuploid and tetraploid tumors. A tumor was regarded as tetraploid if the fraction of nuclei in the region corresponding to the diploid G 2 /M peak exceeded the fraction of cells in S-phase of the diploid stemline, or if a separate G 2 peak appeared in the octaploid position.
Randomization
The study was planned as a multicenter trial with central randomization, by telephone call to the co-ordinating center (NRH). Treatment lists were generated from tables of random numbers stratified by center.
Once the patient was entered into the study she was followed regardless of possible protocol violations.
Patients were allocated to receive carboplatin (Paraplatin 1 ) diluted in 500 ml 5% glucose and infused over 60 minutes dosed at AUC 7 according to Calvert's formula [AUC x (GFR + 25) mg] for 6 courses with 4 weeks interval or no further treatment (control).
Statistical methods
Differences in proportions were evaluated by the chi-square or Fisher's exact test, whichever was appropriate. Disease-free (DFS) and diseasespecific survival (DSS) rates were calculated using the method of Kaplan and Meier [30] . Regarding DFS patients were censored when last seen without recorded progression and for DSS when last seen alive. In both cases patients were also censored at the time of death from causes not related to treatment complications or ovarian cancer. The cause of death was directly reported to the trials office or determined from medical records or death certificates. The log-rank Cox tests were used for univariate analysis and a Cox proportional hazards regression model was used for multivariate evaluation of differences in survival [31] . In the multivariate analyses, only those factors with a /'-value <0.1 in the univariate analysis were considered for inclusion in the models. Forward and backward stepwise selection procedures were used. In the group of patients with diploid tumors no death of disease was registered. To be able to perform Cox analyses regarding DSS we had to register one of the patients as dead of disease. We thus under estimated the prognostic value of DNA-ploidy. The choice of various patients for this procedure resulted in only negligible differences in results. The Statistical Package for Social Science (SPSS) was used. Statistical significance was defined as a two-sided /"-value < 0.05.
Follow-up procedures
Follow-up examinations were done either at the participating hospitals or at referring hospitals. All patients were also followed with help of the Norwegian and Swedish Cancer Registries. No patients were lost to follow-up. WHO criteria for early and late toxicity were used. The diagnosis of progression was based on clinical and radiological examinations and serial serum CA125 measurements and confirmed by cytologic or histologic findings. Routine second look surgery was not done. Treatment at progression consisted of various types of platinumbased chemotherapy.
Results
After exclusion of the 13 ineligible patients 81 each were randomized to carboplatin or observation (control). The characteristics of the patients are summarized in Table 1 .
Flow-cytometry
The DNA analysis was not performed in 13 patients (7%). Of the remaining 149 DNA histograms 37 (25%) were classified as diploid and 112 (75%) as non-diploid. Of the non-diploid tumors 82 (73%) were aneuploid and 30 (27%) were tetraploid.
DFS in months
Survival results from the adjuvant treatment
With a median follow-up of 46 months (range 10-80) no patients died of intercurrent disease or toxicity to treatment. Progression was observed in 39 patients, 20 in the treatment group and 19 in the control group. Of these 39 patients 7 are alive and NED (3 in the treatment group versus 4 in the control group), 14 are alive with disease (8 vs. 6) and 18 (9 in both groups) are dead of disease. Kaplan-Meyer plots of DSS and DFS according to randomization groups are shown in Figure la and lb, respectively. The hazard ratio (HR) is 0.98 in favor of the treatment group regarding DFS with 95% confidence interval (95% CI) from 0.52-1.83 while the HR is 0.94 (95% CI: 0.37-2.36) also in favor of the treatment group regarding DSS. No significant differences in DSS or DFS between the two groups was seen when the log-rank test was stratified for age, FIGO sub-stage, histology, grade, extra capsular growth, rupture of capsule, positive peritoneal washings, presence of ascites, adhesions, tumor size, menopausal status, or DNA ploidy. Therefore the data from both groups were pooled to increase the statistical power when prognostic factors were analyzed.
Univariate analysis of prognostic factors
The variables subject to univariate analyses were, FIGO substage, histologic grade (including clear cell carcinomas in grade 3), DNA ploidy, extra capsular growth, histologic type, rupture of tumor capsule, adhesions, presence of ascites, cytology of ascites or peritoneal washings, tumor size, menopausal status, and age at We specially examined the effect on the probability of relapse and survival on the timing of capsular rupture, i.e., whether it occurred during surgery or prior to surgery. We found that if the capsule ruptured, it had a significantly negative impact both on DFS and DSS (P = 0.02 and P = 0.002, respectively). However, no difference between pre-and intraoperative rupture was found.
Multivariate analysis
A multivariate Cox proportional hazard regression analysis identified independent prognostic parameters related to DFS and DSS. Only factors from the univariate analyses with P < 0.1 were included. Regarding DFS it was FIGO sub-stage, histologic grade, DNA ploidy, extra capsular growth, rupture of capsule, fluid cytology, and menopausal state and for DSS the same factors with the addition af adherences. DNA-ploidy (P -0.003), extracapsular growth (P = 0.005), tumor rupture (P -0.04), and histologic grade (P = 0.04) were identified as significant independent prognostic variables for DFS with P < 0.0001 for the model. A model substituting FIGO substage for extracapsular growth and tumor rupture was almost as strong. The model for DSS (/> < 0.0001) included FIGO substage (P = 0.01), DNAploidy (P < 0.05), and histologic grade (P = 0.05). Table 2 shows the P-values and hazard ratios with 95% CI for DFS and DSS.
Sites of progression
All eligible patients fulfilled the minimum criteria of surgical staging. During the last three years of the study period, most patients had complete pelvic and paraaortic lymph node staging. However, there was no difference in DSS or DFS rate between the two staging groups (optimal versus suboptimal staging). Progression sites involved the pelvis in 6 of 39 patients (15%), the abdomen in 23 of 39 patients (56%), lymph nodes in 6 of 39 (15%), and extra abdominal sites in 4 of 39 (10%). An interesting observation was that six recurrences occurred in fully lymph node staged patients.
Discussion
The key questions regarding adjuvant treatment of early ovarian carcinoma are: 1) what therapeutic options are reasonable? 2) Do any of the existing adjuvant therapies benefit patients? 3) Can patients be prospectively identified who have a sufficiently high risk for progression to justify adjuvant therapy? The 1994 NIH Consensus Conference in Washington DC [32] opined that patients with stage la and Ib, grade 1 tumor had an inherently good prognosis and were unlikely to benefit from adjuvant therapy and this statement is today accepted by virtually all specialists in gynecologic oncology. The same consensus panel also opined that all other early stage patients required postoperative adjuvant therapy. Since this recommendation is not evidence-based it has not been universally accepted by all specialists in gynecologic oncology [8, 17, 19, 33] .
What have we learned from clinical trials of early-stage epithelial ovarian cancer over the past 20 years?
Colombo [34] has summarized the results of randomized trials in early stage ovarian cancer and concluded that none of these studies have shown a survival advantage for either postoperative chemotherapy or irradiation. Small sample sizes may have prevented detection of important differences in clinical outcome. Morbidity, however, was higher after external radiotherapy or treatment with intra-peritoneal radioactive isotopes. Some patients with early stage disease may benefit from adjuvant treatment, but this will be impossible to prove without an observation arm. The need for additional randomized trials is obvious.
Only three randomized studies have so far included a control arm. In the first study of the Gynecologic Oncology Group (GOG) only 86 patients were randomized between pelvic irradiation, melphalan therapy or no treatment [35] . In the second trial also reported by GOG [19] they randomized 81 patients with grade 1 and grade 2 FIGO (1973) stage la, or Ib between adjuvant melphalan therapy and no treatment. This study had serious methodological errors and several patients were removed from the analysis. No difference in the estimated five-year overall survival (OS) was observed between treatment and no treatment in those two GOG studies. There were two cases of drug-induced acute myelogenous leukemia in the treated group. The third study was reported by the Italian GICOG [22] . Eightythree patients with stage la or Ib grade 1 or 2 were randomized to postoperative cisplatinum versus no treatment. There was a statistically significant difference in DFS in favor of cisplatin, but not in OS. All three studies had very low power because of small number of patients and events.
In an effort to answer the question about the value of adjuvant chemotherapy after surgery in high-risk ovarian cancer we started a Scandinavian (NOCOVA) randomized trial in 1992 comparing carboplatinum with observation [23] . At the same time, two other prospective studies in high risk stage I ovarian cancer were initiated in Europe comparing carboplatinum with observation (ACTION and ICON I) [36] . In the NOCOVA study, we calculated that with 300-350 patients there would be an 80% chance of detecting a 15% survival advantage (70%-85%). Accrual has been slow because many patients refused to participate because they were biased against the control arm. A smaller number were biased against the treatment arm. After five years of slow recruitment the study was closed as non-feasible. We could not show any significant difference in DFS or DSS between the treatment arms (Figures la and b) . Unfortunately, the small numbers allow no firm statement regarding benefit or lack thereof of adjuvant therapy. It is quite possible, however, that a difference could exist, since the hazard ratio for immediate treatment with carboplatin relative to observation and treatment at progression has a confidence interval from 0.52-1.83 regarding DFS. An illustration of the number of patients needed to demonstrate effects in studies of adjuvant therapy in early stage disease is that the positive effects of adjuvant therapy in early breast cancer could not be convincingly shown until almost 30,000 patients from several randomized studies were subjected to a metaanalysis [37] .
Can high-risk patients be identified?
Grade, histologic type, dense adhesions, large volume ascites, age, and FIGO sub-stage have been identified as independent prognostic factors that predict for relapse and survival in earlier studies [6] [7] [8] [9] [10] [11] [12] [13] 17] .Vergote et al. [38] in a meta-analysis of 5 studies comprising 1287 patients with FIGO stage I invasive epithelial ovarian cancer found, using a Cox regression analysis, that degree of differentiation followed by FIGO 1973 substage and age, were most predictive prognostically. In the present study grade was an independent prognostic parameter both for DFS (P -0.04) and DSS (P = 0.05) ( Table 2 ). Since the degree of differentiation has repeatedly been identified as an independent prognostic factor in stage I ovarian cancer this variable should be included in a new FIGO staging classification.
The potential clinical use of DNA cytometry for prognostic purposes in ovarian cancer has received much recent attention [17, 39, 40] . However, most previous reports of DNA cytometry for prognostic purposes are limited to stage III and IV disease or include less than 35 stage I patients [41] [42] [43] . Few papers have correlated DNA ploidy in stage I ovarian epithelial carcinoma with more conventional prognostic factors on DFS or DSS. Scheueler et al. [44] performed flow cytometric analysis on well differentiated early-stage I tumors and reported that aneuploidy did not predict for recurrent disease. However, a DNA-index greater than 1.4 was statistically significantly associated with poor prognosis. Vergote et al. [17] identified degree of differentiation as the most powerful predictor of DFS followed by DNA ploidy and finally FIGO 1988 sub-stage in a multivariate analysis of 290 patients. None of the other conventional prognostic factors had independent prognostic significance. These results, allowed classification into risk groups: the low-risk group consisted of patients with well or moderately differentiated, DNA diploid, stage I tumors. None of these patients relapsed, and Vergote et al. [17] strongly suggested that DNA ploidy should be incorporated into future studies as one of the most important prognostic factors.
No studies, except the present, have evaluated the prognostic significance of DNA ploidy in stage I tumors, prospectively. It shows that for DFS the independent prognostic factors were in order 1) DNA-ploidy, 2) extracapsular growth, and 3) tumor rupture and histologic grade (Table 2) . Substituting extracapsular growth and tumor rupture with FIGO substage resulted in little loss of the prognostic power of the model. It should also be noted that, because of the inclusion criteria for the study, all grade I tumors were aneuploid. For DSS the independent prognostic factors were 1) FIGO substage, and 2) DNA ploidy and 3) histologic grade.
The independent significance of tumor rupture is still controversial [6, 7, 13, 33, 38, [45] [46] [47] [48] . The Vergote study [17] showed little prognostic significance for rupture or extra capsular growth when analyzed separately. But aggregating rupture, extra capsular growth and ascites into one variable, as in the FIGO (1988) staging system, had a significant prognostic power. In a meta-analysis [38] comprising 1287 FIGO stage I cases patients without rupture had a five-year DFS of 83%, compared to 80% with rupture during surgery, and 68% with rupture prior to surgery. The difference between no rupture and rupture during surgery was not significant whereas there was a significant difference between no rupture and rupture prior to surgery (P = 0.002). All the abovementioned studies were done, retrospectively. In the multivariate analysis of the present study capsule rupture was found to be an independent prognostic parameter regarding DFS but not DSS (Table 2 ). This discrepancy may be because capsule rupture is included in FIGO substage and FIGO substage is a stronger prognostic factor than capsule rupture regarding DSS. Our data support the validity of the subclassification of stage I in the FIGO 1988 staging system which includes the parameters capsule rupture, and extra capsular growth.
In the present study, complete and more aggressive staging as defined by Young et al. 1987 [49] , did not select a group with improved outcome. The same was found in the Italian GICOG study by Bolis et al. [22] in which lymphadenectomy did not appear to play an important prognostic or therapeutic role. Overall the DFS was the same in the suboptimal stage group as in the optimal stage group. Conversely, Zanetta [50] , and others [51] [52] [53] have found that meticulous surgical staging influences survival, particularly in stage I, grade 3 carcinomas.
In conclusion, this prospective randomized trial of adjuvant chemotherapy with carboplatin versus observation and treatment at relapse is unfortunately inconclusive as regards the main question with superimposable survival curves, but with wide confidence intervals. However, the second goal of the study was to evaluate DNA-ploidy as an additional objective prognostic factor in early ovarian cancer. In the multivariate analysis we show that DNA-ploidy adds independent prognostic information to the established prognostic factors FIGO 1988 sub-stage and histological grade. We suggest that DNA ploidy should be included as a prognostic factor when planning future studies in high-risk stage I patients. We also propose that DNA-ploidy should be included in a new FIGO staging system.
